CT55
gene geneOn this page
Also known as FLJ20527
Summary
CT55 (cancer/testis antigen 55, HGNC:26047) is a protein-coding gene on chromosome Xq26.3, encoding Cancer/testis antigen 55 (Q8WUE5). Plays a role in spermatogenesis, possibly acting in the regulation of the autophagy pathway.
Involved in spermatogenesis. Located in acrosomal vesicle and sperm flagellum. Implicated in X-linked spermatogenic failure 7.
Source: NCBI Gene 54967 — RefSeq curated summary.
At a glance
- Gene–disease (curated): spermatogenic failure, X-linked, 7 (Limited, GenCC)
- Clinical variants (ClinVar): 17 total — 1 pathogenic
- Phenotypes (HPO): 14
- MANE Select transcript:
NM_001031705
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26047 |
| Approved symbol | CT55 |
| Name | cancer/testis antigen 55 |
| Location | Xq26.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ20527 |
| Ensembl gene | ENSG00000169551 |
| Ensembl biotype | protein_coding |
| OMIM | 301105 |
| Entrez | 54967 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000276241, ENST00000344129
RefSeq mRNA: 2 — MANE Select: NM_001031705
NM_001031705, NM_017863
CCDS: CCDS14647, CCDS35400
Canonical transcript exons
ENST00000276241 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001126635 | 135156540 | 135157028 |
| ENSE00001300814 | 135157316 | 135157503 |
| ENSE00001309025 | 135171078 | 135171398 |
| ENSE00001644388 | 135160411 | 135160555 |
| ENSE00001663689 | 135158199 | 135158311 |
| ENSE00001670525 | 135169594 | 135169778 |
Expression profiles
Bgee: expression breadth broad, 59 present calls, max score 81.22.
Top tissues by expression
96 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 81.22 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 79.33 | gold quality |
| right testis | UBERON:0004534 | 66.44 | gold quality |
| testis | UBERON:0000473 | 65.09 | gold quality |
| left testis | UBERON:0004533 | 63.89 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 56.11 | gold quality |
| primary visual cortex | UBERON:0002436 | 50.98 | gold quality |
| ventricular zone | UBERON:0003053 | 48.41 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 47.89 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 47.70 | gold quality |
| prefrontal cortex | UBERON:0000451 | 47.65 | gold quality |
| sural nerve | UBERON:0015488 | 47.64 | gold quality |
| frontal cortex | UBERON:0001870 | 46.37 | gold quality |
| cerebral cortex | UBERON:0000956 | 46.30 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 46.16 | gold quality |
| putamen | UBERON:0001874 | 45.97 | gold quality |
| temporal lobe | UBERON:0001871 | 44.53 | gold quality |
| nucleus accumbens | UBERON:0001882 | 44.52 | gold quality |
| amygdala | UBERON:0001876 | 44.40 | gold quality |
| adrenal tissue | UBERON:0018303 | 44.38 | silver quality |
| Ammon’s horn | UBERON:0001954 | 43.89 | gold quality |
| cortex of kidney | UBERON:0001225 | 43.73 | gold quality |
| caudate nucleus | UBERON:0001873 | 43.63 | gold quality |
| right frontal lobe | UBERON:0002810 | 43.49 | gold quality |
| bone marrow cell | CL:0002092 | 43.30 | gold quality |
| brain | UBERON:0000955 | 41.83 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 40.98 | gold quality |
| hypothalamus | UBERON:0001898 | 40.96 | gold quality |
| adrenal gland | UBERON:0002369 | 40.35 | silver quality |
| left adrenal gland cortex | UBERON:0035825 | 40.31 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 1.97 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
46 targeting CT55, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6748-5P | 100.00 | 65.81 | 1057 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-4725-3P | 99.96 | 69.53 | 2520 |
| HSA-MIR-6780B-5P | 99.96 | 69.60 | 2562 |
| HSA-MIR-302E | 99.96 | 70.74 | 2669 |
| HSA-MIR-302A-3P | 99.89 | 71.23 | 1777 |
| HSA-MIR-302B-3P | 99.89 | 71.23 | 1777 |
| HSA-MIR-302C-3P | 99.89 | 71.20 | 1778 |
| HSA-MIR-302D-3P | 99.89 | 71.25 | 1777 |
| HSA-MIR-9902 | 99.89 | 69.15 | 2250 |
| HSA-MIR-4271 | 99.88 | 68.32 | 2244 |
| HSA-MIR-548D-3P | 99.87 | 70.67 | 4362 |
| HSA-MIR-30A-3P | 99.87 | 69.74 | 2928 |
| HSA-MIR-30D-3P | 99.87 | 69.92 | 2917 |
| HSA-MIR-30E-3P | 99.87 | 69.68 | 2942 |
| HSA-MIR-548BB-3P | 99.86 | 70.58 | 4354 |
| HSA-MIR-548AC | 99.84 | 70.77 | 4351 |
| HSA-MIR-548H-3P | 99.84 | 70.80 | 4349 |
| HSA-MIR-548Z | 99.84 | 70.80 | 4349 |
| HSA-MIR-373-3P | 99.84 | 70.68 | 1668 |
| HSA-MIR-520E-3P | 99.84 | 70.55 | 1698 |
| HSA-MIR-1323 | 99.83 | 69.89 | 2471 |
| HSA-MIR-372-3P | 99.83 | 70.58 | 1691 |
| HSA-MIR-520A-3P | 99.83 | 70.59 | 1687 |
| HSA-MIR-520B-3P | 99.83 | 70.56 | 1699 |
| HSA-MIR-520C-3P | 99.83 | 70.56 | 1699 |
| HSA-MIR-520D-3P | 99.83 | 70.78 | 1676 |
| HSA-MIR-8076 | 99.78 | 68.52 | 1170 |
| HSA-MIR-548O-3P | 99.74 | 69.30 | 2228 |
| HSA-MIR-8084 | 99.73 | 69.57 | 1760 |
Literature-anchored findings (GeneRIF, showing 3)
- A novel BRCA2-interacting protein, BJ-HCC-20A, which is reported to be a potential cancer-testis antigen, was identified. (PMID:18307534)
- the relapse rate of CXorf48-specific CTL-negative patients was 63.6%, compared to 0% in CXorf48-specific CTL-positive patients. These results indicate that CXorf48 could be a promising therapeutic target of LSCs for immunotherapy to obtain durable treatment-free remission in CML patients. (PMID:28862699)
- Deficiency of cancer/testis antigen gene CT55 causes male infertility in humans and mice. (PMID:36481789)
Cross-species orthologs
16 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | setx | ENSDARG00000022996 |
| danio_rerio | dna2 | ENSDARG00000078759 |
| rattus_norvegicus | LOC120099287 | ENSRNOG00000070753 |
| rattus_norvegicus | ENSRNOG00000074002 | |
| rattus_norvegicus | ENSRNOG00000082477 | |
| rattus_norvegicus | ENSRNOG00000090738 | |
| rattus_norvegicus | ENSRNOG00000090861 | |
| rattus_norvegicus | ENSRNOG00000091088 | |
| drosophila_melanogaster | CG6701 | FBGN0033889 |
| drosophila_melanogaster | Mov10 | FBGN0034187 |
| drosophila_melanogaster | armi | FBGN0041164 |
| drosophila_melanogaster | Dna2 | FBGN0288690 |
| caenorhabditis_elegans | WBGENE00001016 | |
| caenorhabditis_elegans | Y106G6D.5 | WBGENE00014965 |
| caenorhabditis_elegans | sosi-1 | WBGENE00016565 |
| caenorhabditis_elegans | eri-7 | WBGENE00016566 |
Paralogs (10): UPF1 (ENSG00000005007), AQR (ENSG00000021776), MOV10L1 (ENSG00000073146), SETX (ENSG00000107290), ZNFX1 (ENSG00000124201), HELZ2 (ENSG00000130589), IGHMBP2 (ENSG00000132740), DNA2 (ENSG00000138346), MOV10 (ENSG00000155363), HELZ (ENSG00000198265)
Protein
Protein identifiers
Cancer/testis antigen 55 — Q8WUE5 (reviewed: Q8WUE5)
Alternative names: Tumor antigen BJ-HCC-20
All UniProt accessions (1): Q8WUE5
UniProt curated annotations — full annotation on UniProt →
Function. Plays a role in spermatogenesis, possibly acting in the regulation of the autophagy pathway.
Subunit / interactions. Interacts with GABARAP; this interaction may be important for GABARAP protein stability. Isoform 1 interacts with LAMP2; this interaction may be important for LAMP2 protein stability.
Subcellular location. Cytoplasm. Cytoplasmic vesicle. Secretory vesicle. Acrosome. Cell projection. Cilium. Flagellum.
Tissue specificity. Testis-specific. Expressed in spermatozoa (at protein level).
Disease relevance. Spermatogenic failure, X-linked, 7 (SPGFX7) [MIM:301106] A male infertility disorder characterized by a significant reduction in sperm count and motility, and aberrant sperm morphology with abnormalities of the head and flagella. Patient sperm show insufficient individualization, excessive residual cytoplasm, and defects in acrosome development. The disease is caused by variants affecting the gene represented in this entry.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q8WUE5-1 | 1, BJ-HCC-20A | yes |
| Q8WUE5-2 | 2, BJ-HCC-20B |
RefSeq proteins (2): NP_001026875, NP_060333 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR012340 | NA-bd_OB-fold | Homologous_superfamily |
| IPR025223 | S1-like_RNA-bd_dom | Domain |
Pfam: PF14444
UniProt features (5 total): chain 1, region of interest 1, compositionally biased region 1, splice variant 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8WUE5-F1 | 75.60 | 0.36 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 68 (showing top):
GOCC_SECRETORY_GRANULE, GOBP_MALE_GAMETE_GENERATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOCC_SECRETORY_VESICLE, GOCC_MOTILE_CILIUM, GOCC_ACROSOMAL_VESICLE, GOCC_CILIUM, chrXq26, GOCC_9PLUS2_MOTILE_CILIUM, KRAS.600_UP.V1_DN, ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP, MIR6780B_5P, MIR4725_3P, MIR6853_3P, MIR12120
GO Biological Process (1): spermatogenesis (GO:0007283)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (7): acrosomal vesicle (GO:0001669), cytoplasm (GO:0005737), sperm flagellum (GO:0036126), cilium (GO:0005929), cytoplasmic vesicle (GO:0031410), motile cilium (GO:0031514), cell projection (GO:0042995)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| developmental process involved in reproduction | 1 |
| male gamete generation | 1 |
| binding | 1 |
| secretory granule | 1 |
| intracellular anatomical structure | 1 |
| 9+2 motile cilium | 1 |
| intraciliary transport particle | 1 |
| membrane-bounded organelle | 1 |
| plasma membrane bounded cell projection | 1 |
| cytoplasm | 1 |
| intracellular vesicle | 1 |
| cilium | 1 |
Protein interactions and networks
STRING
658 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CT55 | CT45A1 | Q5HYN5 | 525 |
| CT55 | CT47A11 | Q5JQC4 | 522 |
| CT55 | GAGE2A | Q6NT46 | 507 |
| CT55 | ACTL8 | Q9H568 | 507 |
| CT55 | EPPIN | O95925 | 506 |
| CT55 | XAGE1B | Q9HD64 | 506 |
| CT55 | A0A1W2PQG5 | A0A1W2PQG5 | 505 |
| CT55 | PASD1 | Q8IV76 | 493 |
| CT55 | MAGEA10 | P43363 | 480 |
| CT55 | SAGE1 | Q9NXZ1 | 480 |
| CT55 | CSAG2 | Q9Y5P2 | 479 |
| CT55 | MAGEC1 | O60732 | 476 |
| CT55 | FTHL17 | Q9BXU8 | 476 |
| CT55 | SSX4 | O60224 | 447 |
| CT55 | SPANXN1 | Q5VSR9 | 447 |
IntAct
105 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CT55 | TXLNB | psi-mi:“MI:0915”(physical association) | 0.670 |
| KIAA0753 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KLHL42 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PIH1D2 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SHC3 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SAMD11 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C2CD6 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KLC3 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KYNU | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| EXOC7 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MEMO1 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| FAAP20 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SNF8 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| LYPLAL1 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| BFSP2 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TLE5 | CT55 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (73): CT55 (Two-hybrid), TXLNB (Two-hybrid), USP4 (Affinity Capture-MS), SYNM (Affinity Capture-MS), UHRF1BP1L (Affinity Capture-MS), VPS33A (Affinity Capture-MS), VPS41 (Affinity Capture-MS), VPS18 (Affinity Capture-MS), VPS16 (Affinity Capture-MS), CNOT1 (Affinity Capture-MS), C12orf45 (Affinity Capture-MS), CNOT8 (Affinity Capture-MS), CNOT10 (Affinity Capture-MS), RQCD1 (Affinity Capture-MS), LRBA (Affinity Capture-MS)
ESM2 similar proteins: A0JNQ6, A2RT67, A2RUS2, A6NC42, A6NGQ2, A9X185, O75031, O75817, O94955, O95267, P50747, Q06VW1, Q0II25, Q0ZFW8, Q1RMS8, Q1RMZ1, Q29108, Q2TBA3, Q3T0J1, Q3TYS2, Q4VX76, Q568D5, Q568M3, Q587J7, Q5JSQ8, Q5T9G4, Q5ZLS2, Q62522, Q69ZK0, Q6AYA6, Q6P5G6, Q7Z7H3, Q80X86, Q86WV5, Q8BXK4, Q8C0Q9, Q8CHQ0, Q8TCU6, Q8WUE5, Q91Z62
Diamond homologs: Q14BQ3, Q8WUE5, Q99MV5, Q9BXT6, P23249, P30771, P34243, P39369, P42694, Q09820, Q0V8H6, Q1LXK4, Q1LXK5, Q54I89, Q5ZKD7, Q6DFV5, Q6J5K9, Q6NYU2, Q86AS0, Q86YA3, Q8GYD9, Q92900, Q9EPU0, Q9FJR0, Q9HCE1, Q9HEH1, Q9VYS3, B6SFA4, F1RCY6, O76512, O94387, Q0VGT4, Q6ZQJ5, Q7Z333, Q9BYK8
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 35 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| intermediate filament organization | 5 | 36.5× | 4e-05 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
17 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 13 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 2499997 | NM_001031705.3(CT55):c.465T>A (p.Tyr155Ter) | Pathogenic |
SpliceAI
899 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| X:135160487:T:TA | donor_gain | 1.0000 |
| X:135169588:TCTCA:T | donor_loss | 1.0000 |
| X:135169589:CTCA:C | donor_loss | 1.0000 |
| X:135169590:TCA:T | donor_loss | 1.0000 |
| X:135169591:CACCT:C | donor_loss | 1.0000 |
| X:135169774:GTCAC:G | acceptor_gain | 1.0000 |
| X:135169775:TCAC:T | acceptor_gain | 1.0000 |
| X:135169776:CAC:C | acceptor_gain | 1.0000 |
| X:135169776:CACC:C | acceptor_gain | 1.0000 |
| X:135169777:AC:A | acceptor_gain | 1.0000 |
| X:135169777:ACC:A | acceptor_gain | 1.0000 |
| X:135169777:ACCT:A | acceptor_loss | 1.0000 |
| X:135169778:CC:C | acceptor_gain | 1.0000 |
| X:135169778:CCT:C | acceptor_gain | 1.0000 |
| X:135169778:CCTA:C | acceptor_loss | 1.0000 |
| X:135169779:C:CC | acceptor_gain | 1.0000 |
| X:135169783:A:T | acceptor_gain | 1.0000 |
| X:135169786:A:C | acceptor_gain | 1.0000 |
| X:135157347:T:A | donor_gain | 0.9900 |
| X:135158198:CCT:C | donor_gain | 0.9900 |
| X:135158312:C:CC | acceptor_gain | 0.9900 |
| X:135160464:T:C | donor_gain | 0.9900 |
| X:135160505:T:TA | donor_gain | 0.9900 |
| X:135169592:A:AC | donor_gain | 0.9900 |
| X:135169593:C:CC | donor_gain | 0.9900 |
| X:135169775:TCACC:T | acceptor_gain | 0.9900 |
| X:135169776:CACCT:C | acceptor_gain | 0.9900 |
| X:135169779:C:A | acceptor_gain | 0.9900 |
| X:135169780:T:A | acceptor_gain | 0.9900 |
| X:135169782:CAAGA:C | acceptor_gain | 0.9900 |
AlphaMissense
1728 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| X:135157447:G:C | F198L | 0.981 |
| X:135157447:G:T | F198L | 0.981 |
| X:135157449:A:G | F198L | 0.981 |
| X:135157345:T:A | R232S | 0.980 |
| X:135157345:T:G | R232S | 0.980 |
| X:135157391:A:T | V217D | 0.979 |
| X:135169696:G:C | F59L | 0.971 |
| X:135169696:G:T | F59L | 0.971 |
| X:135169698:A:G | F59L | 0.971 |
| X:135158307:A:C | F143L | 0.969 |
| X:135158307:A:T | F143L | 0.969 |
| X:135158309:A:G | F143L | 0.969 |
| X:135157346:C:G | R232T | 0.962 |
| X:135157448:A:G | F198S | 0.960 |
| X:135157409:G:T | P211H | 0.957 |
| X:135157343:G:T | A233E | 0.955 |
| X:135169745:A:T | V43D | 0.955 |
| X:135157472:C:T | G190E | 0.950 |
| X:135158290:T:G | D149A | 0.950 |
| X:135158290:T:C | D149G | 0.949 |
| X:135157369:G:C | S224R | 0.947 |
| X:135157369:G:T | S224R | 0.947 |
| X:135157371:T:G | S224R | 0.947 |
| X:135157347:T:C | R232G | 0.944 |
| X:135158291:C:G | D149H | 0.943 |
| X:135158284:A:G | L151S | 0.939 |
| X:135158302:G:T | P145H | 0.939 |
| X:135157410:G:A | P211S | 0.938 |
| X:135157450:A:C | F197L | 0.937 |
| X:135157450:A:T | F197L | 0.937 |
dbSNP variants (sampled 300 via entrez): RS111378411 (X:135158618 T>G), RS111527783 (X:135159600 T>C), RS111593484 (X:135164100 G>A), RS111629738 (X:135158131 T>G), RS112085692 (X:135169968 T>A), RS112336234 (X:135164126 C>G,T), RS113172956 (X:135169811 G>A), RS1156375591 (X:135171846 A>G), RS1156678956 (X:135169010 T>A), RS1156888676 (X:135159971 G>A), RS1157160436 (X:135162747 C>T), RS1157167110 (X:135157717 G>A), RS1157587313 (X:135159058 C>T), RS1157729350 (X:135159551 C>T), RS1157950505 (X:135158452 CT>C)
Disease associations
OMIM: gene MIM:301105 | disease phenotypes: MIM:301106
GenCC curated gene-disease
| Disease | Classification | Inheritance |
|---|---|---|
| spermatogenic failure, X-linked, 7 | Limited | Unknown |
Mondo (1): spermatogenic failure, X-linked, 7 (MONDO:0957202)
Orphanet (0):
HPO phenotypes
14 total (14 of 14 shown, HPO-id order):
| HPO | Term |
|---|---|
| HP:0000027 | Azoospermia |
| HP:0000118 | Phenotypic abnormality |
| HP:0000837 | Increased circulating gonadotropin level |
| HP:0001417 | X-linked inheritance |
| HP:0003251 | Male infertility |
| HP:0008669 | Abnormal spermatogenesis |
| HP:0008734 | Decreased testicular size |
| HP:0011462 | Young adult onset |
| HP:0011961 | Non-obstructive azoospermia |
| HP:0011962 | Obstructive azoospermia |
| HP:0012205 | Globozoospermia |
| HP:0012207 | Reduced sperm motility |
| HP:0034309 | Multiflagellar spermatozoa |
| HP:0034795 | Excess residual spermatozoal cytoplasm |
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
5 total (human), top 5 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Associated diseases: spermatogenic failure, X-linked, 7
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): spermatogenic failure, X-linked, 7